Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony?

Steve R. Martinez, Dave S B Hoon

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.

Original languageEnglish (US)
Pages (from-to)473-483
Number of pages11
JournalJournal of Cellular Biochemistry
Volume96
Issue number3
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

Gift Giving
Biomarkers
Horses
Melanoma
RNA
Poisons
DNA
Assays
Therapeutics
Morbidity
Recurrence
Survival
Cutaneous Malignant Melanoma

Keywords

  • DNA
  • Melanoma
  • Molecular markers
  • qRT
  • RNA
  • RT-PCR

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Molecular markers in malignant cutaneous melanoma : Gift horse or one-trick pony? / Martinez, Steve R.; Hoon, Dave S B.

In: Journal of Cellular Biochemistry, Vol. 96, No. 3, 15.10.2005, p. 473-483.

Research output: Contribution to journalArticle

Martinez, Steve R. ; Hoon, Dave S B. / Molecular markers in malignant cutaneous melanoma : Gift horse or one-trick pony?. In: Journal of Cellular Biochemistry. 2005 ; Vol. 96, No. 3. pp. 473-483.
@article{5849cc464c32484499a8c5d9fa9aef9f,
title = "Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony?",
abstract = "The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.",
keywords = "DNA, Melanoma, Molecular markers, qRT, RNA, RT-PCR",
author = "Martinez, {Steve R.} and Hoon, {Dave S B}",
year = "2005",
month = "10",
day = "15",
doi = "10.1002/jcb.20556",
language = "English (US)",
volume = "96",
pages = "473--483",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Molecular markers in malignant cutaneous melanoma

T2 - Gift horse or one-trick pony?

AU - Martinez, Steve R.

AU - Hoon, Dave S B

PY - 2005/10/15

Y1 - 2005/10/15

N2 - The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.

AB - The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.

KW - DNA

KW - Melanoma

KW - Molecular markers

KW - qRT

KW - RNA

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=27144558065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144558065&partnerID=8YFLogxK

U2 - 10.1002/jcb.20556

DO - 10.1002/jcb.20556

M3 - Article

C2 - 16088931

AN - SCOPUS:27144558065

VL - 96

SP - 473

EP - 483

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 3

ER -